pharma-congress-molecular-medicine-2018-posters

Page 40

O c t o b e r 1 9 - 2 0 , 2 0 1 8 | T o k y o , J a p a n

Pharma Congress 2018 & Molecular Medicine 2018

& Psychiatric Disorders 2018

Asian Journal of Biomedical and Pharmaceutical Sciences

ISSN: 2249-622X

Volume 8

International Conference on

PHARMACEUTICS AND NOVEL DRUG DELIVERY SYSTEMS

International Conference on

CELLULAR AND MOLECULAR MEDICINE

Annual Congress on

PSYCHIATRY AND PSYCHIATRIC DISORDERS

OF EXCELLENCE

IN INTERNATIONAL

MEETINGS

YEARS

Asian J Biomed Pharmaceut Sci 2018, Volume 8 | DOI: 10.4066/2249-622X-C3-009

MOLECULAR PROFILING AND PERSONALIZED MEDICINE OF NON-SMALL

CELL LUNG CANCER AND COLORECTAL CANCER

Dongfeng Tan

University of Texas, USA

ersonalized medicine, in concert with targeted oncologic therapy, has become one of the most active, rapidly advancing, and

clinically challenging pursuits in cancer treatment. A major concern for molecular geneticists and clinicians must be to focus

upon prioritizing those issues that are most important for research and targeted management in these most prolific days of cancer

medicine. In no area of medicine is this more apparent than in cancer medicine, where arrays of specific genetic alterations have

been used to manage various types of malignancies. The discoveries that form our understanding of cancer have substantially ac-

celerated over the past decade. These emerging findings have significantly affected the traditional practice of oncology and have

resulted in a subspecialized multidisciplinary approach to patient care that incorporates personalized therapies such as targeted

molecular therapy, prognosis, risk assessment, and prevention, all of which are primarily based on molecular diagnostics and im-

aging. This presentation, using non-small cell lung cancer and colorectal cancer as models, updates readers on recently acquired

knowledge of molecular pathology and emphasizes new uses for that knowledge in the changing landscape of specialized multi-

disciplinary care and personalized medicine. Novel therapeutic agents against specific genetic, molecular, and antigenic targets

are discussed, as is the process for deciding whether to use these agents. Furthermore, recent developments in targeting cancer

stem cell to avoid drug resistance, recurrence and metastasis are to be discussed.